EFTA01368453.txt Text dataset_10 View on DOJ

Illegal Activity
none
Blackmail
none
Date
2015-06-15
Document Type
news article
Model
gemini-2.0-flash-001
Processed
2026-02-07T18:41
Summary
Avalanche Biotechnologies Inc. shares dropped after a gene therapy trial for wet AMD missed expectations, requiring patients to still need injections. The article discusses the potential impact of AVA-101 on the market and the current treatments by Regeneron and Roche.
Metadata
Subject
Avalanche Drops as Gene Therapy Trial Miss High Expectations
Sender
Recipients
Document ID
DB-SDNY-0060194
Date
2015-06-15
Relationships 2
Entity 1RelationshipEntity 2Description
Avalanche Biotechnologies Inc. business Roche Holding AG Avalanche's AVA-101 is compared to Roche's Lucentis.
Avalanche Biotechnologies Inc. business Regeneron Pharmaceuticals Inc. Avalanche's AVA-101 is compared to Regeneron's current options.
Notable Quotes 2
"When a company is valued at $1 billion at a phase 2 trial, the expectations are quite high,"
"Our goal is to bring this to the majority of wet AMD patients who have a need for frequent injections."
Financial Information
Amounts:$1 billion$26.40$1.7 billion
Media & Journalist References
  • Danielle Burger
  • Cra ton Harrison
  • Gary Putka
Public Knowledge
Context
News about pharmaceutical trials and stock market reactions are often of public interest.
Media Worthy
Yes
Raw Analysis JSON click to expand
Themes
Financial transactions/money flowLegal matters/litigationBusiness dealingsCommunications/correspondence
Organizations 4
Avalanche Biotechnologies Inc.Roche Holding AGChardan Capital MarketsRegeneron Pharmaceuticals Inc.
Locations 2
New YorkU.S.
Text Analysis
Tone
neutral
Purpose
To report on the drop in Avalanche Biotechnologies Inc. shares after a gene therapy trial missed expectations.
Significance
The article discusses the potential of AVA-101, a gene therapy for wet AMD, and its impact on the market currently dominated by Regeneron and Roche.
File Info
File Name
EFTA01368453.txt
Dataset
dataset_10
Type
Text
Model
gemini-2.0-flash-001
Processed
2026-02-07T18:41:02.198587
DOJ Source
View on DOJ